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staging system. However, the TNM staging system is not sufficient for treatment decisions and prognosis prediction of patients with CRC. [2] [3] [4] For example, patients with stage IIB CRC tend to show poor prognosis, with a 5-year relative survival rate of 46%-61% compared with those with stage IIIA (~70%). 5, 6 This limitation of TNM staging indicates an increasing and urgent need for identifying novel biomarkers to improve the outcome and treatment of patients with CRC.
With the application of muti-omics technologies to study CRC, it was demonstrated that CRC is of high heterogeneity at the intertumoral and intratumoral levels. Patients with CRC often have variable prognosis and treatment responses, even in tumours that are histologically identical. 7 Advances in molecular profiling have enabled a better understanding of CRC development and provide additional clinically relevant prognostic information beyond the current classic staging system. 8 During the past years, across different independent datasets. 9 The potential issues preventing the translation of in silico data into clinical practice include (a) the fact that these existing signatures were usually generated from a small sample size or a single dataset; (b) did not account for biological heterogeneity and technical biases across different datasets, which led to overfitting and concentrating on the discovery dataset; and (c) insufficient independent validation. These limitations highlighted the requirement for adequate sample size and multi-institutional patient cohorts for sufficient statistical power when trying to identify a robust prognostic signature. 10 Another major concern for low reproducibility is that these signatures only focus on statistical values and often fail to incorporate the biological rationale, thus leading to the incorporation of unrelated genes, which are correlative rather than causative. 11, 12 Therefore, it is necessary to explore novel personalized and reproducible prognostic signatures based on multi-institutional cohorts of patients with CRC of sufficient size to aid clinical decision-making and improve the outcomes of patients with CRC.
The present study combined large-scale gene expression profiles and clinical data of patients with CRC from multi-centre studies and developed a novel computational framework to identify a function-derived personalized gene signature (FunPGS) for improving outcome. This prognostic signature was validated in multiple independent datasets across different technology platforms, and its performance was assessed in comparison to recently proposed signatures.
| MATERIAL S AND ME THODS

| Patient cohorts and study design
To obtain datasets of patients with CRC, a comprehensive database search for CRC studies was conducted, which included patient datasets according to following selection criteria: (a) Datasets with genome-wide transcriptional profiles and clinicopathological annotations; and (b) datasets with large sample size (n > 50).
Finally, a total of 1828 patients from 10 public CRC datasets were analysed in the present study, including nine microarray datasets from the Gene Expression Omnibus (GEO, https ://www.ncbi.nlm.
nih.gov/geo/) database and one RNA-Seq dataset of The Cancer Genome Atlas (TCGA) from the UCSC Xena project (https ://xena.
ucsc.edu/).
To minimize undesired bias across the datasets, seven datasets profiled on the same array platform (Affymetrix U133 Plus 2.0 Array) were selected as the meta-training cohort. The remaining TA B L E 1 CRC patient datasets enrolled in the study three patient datasets profiled with different platforms and outcome measure were utilized as an independent testing cohort for validating the prognostic value of the signature. Detailed information about these 10 CRC datasets is shown in Table 1 and Table S1 .
| Pre-processing of profiling data
Raw microarray datasets (.CEL files) from the GEO database were pre-processed and normalized using the Robust Multi-array Average (RMA) algorithm for background correction, log 2 -transformation and quantile normalization using the R package 'affy'. All microarray probes were mapped to Entrez Gene ID, and the mean value of multiple probes mapping to the same gene ID was used to represent the gene expression level using the R package 'limma'. To avoid systematic measurement bias, each microarray datum was normal- 
| Gene set function analysis
Gene Ontology (GO) function enrichment analysis of the prognostic gene sets was performed using the R package 'clusterProfiler'. 13 GO terms with P < 0.01 were considered to be significantly different and were selected for further analysis. Significantly enriched GO terms were clustered and visualized using the Enrichment Map plugin in Cytoscape. 14 Functional similarity among different sets of enriched GO terms was computed using the R package 'GOSemSim'. 
| Statistical analysis
Survival analysis, including univariate and multivariate analyses with Cox proportional hazards regression and Kaplan-Meier analysis with log-rank test was performed using the R package 'survival'. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.
Harrell's concordance index (C-index) was calculated for each dataset to evaluate its prognostic performance using the R package 'survcomp'. Time-dependent ROC curves and AUC at 3-and 5-years were calculated to assess the predictive performance of molecular signature in comparison with clinical prognostic factors (stage and age) using the R package 'timeROC'. Meta-analysis was performed using
F I G U R E 1 Schematic representation of the computational workflow to derive and validate a function-derived gene signature as a personalized prognostic predictor of outcome in patients with colorectal cancer the R package 'meta'. Because of potential heterogeneity among clinical samples and studies, heterogeneity among studies was assessed using the Higgins' I 2 and Q statistics. When heterogeneity existed among studies (P < 0.1 and I 2 > 50%), random-effect models were used for the meta-analyses. Otherwise, the fixed-effect model was employed. Similarity of gene membership between each prognostic signature pair was assessed by the Jaccard index. All statistical analyses were performed using R (v3.3.3) and Bioconductor.
| RE SULTS
| Consistency evaluation of prognostic gene sets from different patient datasets
The association of genes with survival was first assessed in each dataset of the meta-training cohort using univariate Cox regression analysis followed by multivariate analysis adjusted by clinical variables including stage, gender and age. This resulted in 
| Construction and definition of the FunPGS
Based on the above observations, the present study developed a computational, statistical function-derived workflow to construct a robust personalized gene signature (Figure 1 Figure 2C ). Then, the FunPGS was constructed from 1192 patients in the meta-training cohort as described in Figure 1 . The FunPGS divided these 1192 patients from the meta-training cohort into two risk groups by the median score, namely patients with low FunPGS (high risk) and patients with high FunPGS (low risk). As shown in Figure 3A , patients predicted as 'high risk' experienced significantly shorter survival compared with those predicted as 'low risk' (high risk vs. low risk, 5-year survival 52% vs.
68%, log-rank test, P < 0.001; HR = 1.824, 95% CI = 1.513-2.199, P < 0.001). Patients with low FunPGS exhibited a higher risk of succumbing to disease than those with high FunPGS (number of mortalities 274 vs. 186, χ 2 test, P < 0.001) ( Figure 3B ). With increasing FunPGS, patients expressed higher levels of protective prognostic genes and lower levels of risk-associated prognostic genes ( Figure 3B ).
The C-index for the FunPGS was estimated in each dataset of the meta-training cohort separately and was integrated using metaanalysis for evaluation of the overall prognostic value of the FunPGS.
The forest plot using the random-effect model indicated a significantly favourable prognostic value for the FunPGS, and the relevant meta-analysis revealed a C-index of 0.62 (95% CI = 0.57-0.66, P < 0.001) ( Figure 3C ). A univariate analysis was conducted for each dataset of the meta-training cohort separately, and a meta-analysis was performed on the meta-training cohort. As shown in the forest plot of Figure 3D , the FunPGS was significantly associated with survival time, with a fixed-effect pooled HR of 0.67 (95% CI = 0.59-0.76, P < 0.001), which confirmed the strong prognostic value of the FunPGS on outcome.
| External validation of the FunPGS on three independent datasets across different technology platforms
The ability of the FunPGS for stratifying patients with CRC and dif- The C-index for the FunPGS was calculated in each of the three independent datasets. As shown in Figure 4F , the FunPGS yielded a significant prognostic value, exhibiting a high C-index in all the independent datasets (GSE14333, C-index = 0.59, P = 0.043; GSE33113, C-index = 0.77, P = 0.004; and TCGA, C-index = 0.76, P < 0.001) ( Figure 4F ).
| Independence of the FunPGS from other clinicopathological factors
To evaluate whether the FunPGS was independent from other clini- These results from multivariate analysis indicated that the predictive power of the FunPGS is independent of other clinicopathological factors and, furthermore, it outperformed other clinicopathological factors.
| Prognostic performance of the FunPGS in comparison with five previously published gene signatures
In the present study, five gene expression-based signatures associated with outcome of patients with CRC were collected retrospectively from previous studies, namely TianSig, 19 PengSig, 20 DaiSig, 21 ChenSig 22 and LiuSig. 23 The present study assessed and 
| Integrated prognostic signature obtained by combining the FunPGS with clinical factors
The AJCC TNM staging system and age are well-known important prognostic factors. 24, 25 In the multivariate analysis conducted in the present study, TNM stage and age remained significantly associated with survival besides the FunPGS in the meta-discovery and TCGA cohorts, indicating the independent and complementary value of TNM stage and age. Therefore, the FunPGS, TNM stage and age were combined to construct an integrated molecular and clinical factors-based prognostic signature (IMCPS), and its prognostic value was tested. The IMCPS was quantified by subjecting the FunPGS, rived from the meta-discovery cohort was used as a cut-off value to stratify patients into low-or high-risk groups. As shown in Figure 7 , the IMCPS had higher separation than the FunPGS alone between the high and low-risk groups in the meta-training cohort and the Figure 7A and 7) . The present study also compared the IMCPS with TNM stage and age by time-dependent ROC analysis and observed that the AUC of the IMCPS was significantly higher than TNM stage and age at 3-year and 5-year OS in both the meta-training cohort and the independent TCGA dataset.
Thus, the IMCPS greatly improved the predictive performance of survival estimation ( Figure 7C and 7) . This may be partly because of heterogeneous prognosis and treatment responses, which may arise from molecular heterogeneity. 8, 26 Therefore, reliable and independent molecular biomarkers capa- 
| D ISCUSS I ON
16,17
The FunPGS was constructed in a meta-training cohort comprising 1192 patients from seven datasets, which overcomes the weakness of small sample size and a single simple source. Limitations in the application of previously proposed signatures have demonstrated the importance of rigorous validation and reproducibility for medical applications. 28 The FunPGS effectively discriminated patients with CRC and significantly different survival and was successfully validated in a completely independent TGCA RNA-seq dataset,
suggesting that the FunPGS is robust and insensitive to technical biases that are inherent to measurements by different platforms. It is well known that the outcome of patients with CRC has improved by the combined treatment of surgical resection and adjuvant chemotherapy. However, because of molecular heterogeneity, a group of patients with a relatively low incidence of recurrence may be (WIBEZD2017009-05). The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
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